Abstract:1 The desensitizing acetylcholine (ACh) response of bovine chromaffin cells maintained in culture was examined using rapid agonist applications (of 2 s duration) which imposed nominal drug concentrations within 50 ms. This study was aimed, firstly, at identifying which of the α3, α4 and α7 subunits known to be present in these cells is predominant in the ACh‐evoked response and secondly, on the effects on these neuronal nicotinic ACh receptors (AChR) of cyclothiazide (CT), an agent acting as a modulator of a gating desensitization site on other ligand‐gated channels. 2 Locally applied 100 μm ACh evoked peak currents (IAch) of −1.5 ± 0.1 nA (n = 83) at a holding potential of −60 mV. The ACh dose‐response curve yielded an estimated EC50 of 60 μm. This current was not sustained but desensitized during the application period; it displayed strong inward rectification, but desensitized equally whether the evoked current was inward or outward going. The latter observation excludes α4 as a major contributor to the recorded current. Because the response was almost insensitive to a 1 μm α‐bungarotoxin pretreatment (IACg = −12 ± 0.1 nA; n = 6), and because 1, 1‐dimethyl‐4‐phenylpiperazinium (DMPP) works as a potent agonist (peak current = −1.9 nA, n = 2 for 100 μm DMPP), the α7 subunit is also a minor contributor to the response. Taken together, these observations suggest a dominant α3 type of response. 3 Triple exponential fits were used to describe the characteristics of the ACh‐evoked currents; one component to fit the rising phase, with 2 components to describe the decay phase. The decay times were 100 ms and 4 s for the fast and slow components respectively. The rate of the slow decay component increased systematically with recording time, approximately doubling from its initial value within 20–40 min. Furthermore there was a gradual rundown of the response, seen first as a loss of the late component of the current, measured at 2 s, with the peak current amplitude decreasing later in the recording. 4 CT, when coapplied with ACh, produced a dose‐dependent inhibition of the ACh‐evoked peak current. The effect showed little voltage‐dependency with 100 μm CT producing 46 ± 5% (s.d.; n = 3) and 47 ± 8% (s.d.; n = 7) inhibition at −100 and −60 mV respectively. At +60 mV, inhibition was estimated to be 26 ± 7% (s.d.; n = 3). 5 After pre‐exposure of the cells to CT by bath application, 10 and 30 μm CT produced poorly reversible 20 ± 9% (n = 7) and 42 ± 5% (n = 4) inhibitions of the peak current respectively. There were no discernible effects on the fitted decay constants at any CT concentration tested, although an increased inhibitory effect of CT was observed at higher concentrations (100 μm) on the amplitude of the late component measured at 2 s. 6 Similar effects were observed in conditions chosen to isolate the α3 type of receptor: namely when using DMPP as an agonist, or after α‐bungarotoxin pretreatment. 7 The 2,3‐benzodiazepine, GYKI 53655, is known to antagonize the action of CT on AMPA receptors. Coapplication of 50 μm GYKI 53655 with ACh (100 μm) produced a 29 ± 4% inhibition of the peak ACh‐evoked current and 44 ± 6% inhibition of its amplitude at 2 s (n = 4). This response was fully reversible. Brief applications of both CT (100 μm) and GYKI 53655 (50 μm) with ACh via the microperfusion system produced a fully reversible inhibition that was not significantly different from the values obtained with either CT or GYKI 53655 alone, with 37 ± 6% inhibition of peak and 61 ± 9% inhibition of the amplitude at 2 s (n = 3). 8 The results obtained suggest that the CT effect is to impede recovery from a slow desensitization, with a more pronounced effect with longer CT applications. Globally, CT favours the ‘rundown state’ of the neuronal nicotinic AChR.

[Transcranial Doppler and cerebral vasospasm].

Feasibility of Acquisitions Using Total-Body PET/CT with an Ultra-Low 18F-FDG Activity.

Feasibility of Acquisitions Using Total-Body PET/CT with an Ultra-Low <SUP>18</SUP>F-FDG Activity

Ultralow-dose [18F]FDG PET/CT Imaging: Demonstration of Feasibility in Dynamic and Static Images

The Feasibility of Ultralow-Activity 18F-FDG Dynamic PET Imaging in Lung Adenocarcinoma Patients Through Total-Body PET/CT Scanner

Establishment of a Normal Control Model of Children's Brain 18-Fluorodeoxyglucose Positron Emission Tomography and Analysis of the Changing Pattern in Patients Aged 0-14 Years

Simulated Reduced-Count Whole-Body FDG PET: Evaluation in Children and Young Adults Imaged on a Digital PET Scanner

The Evaluation on the Image Quality of a Total-Body PET/CT Imaging with an Ultra-Low Injected Dose

Inhibition by cyclothiazide of neuronal nicotinic responses in bovine chromaffin cells

Dose Reduction in Pediatric Oncology Patients with Delayed Total-Body [ 18 F]FDG PET/CT

Sedation-free pediatric [18F]FDG imaging on totalbody PET/CT with the assistance of artificial intelligence

Dynamic Total-Body PET/CT Imaging with Reduced Acquisition Time Shows Acceptable Performance in Quantification of [ 18 F]FDG Tumor Kinetic Metrics

Image quality and lesion detectability in low-dose pediatric 18F-FDG scans using total-body PET/CT

Evaluation of pediatric malignancies using total-body PET/CT with half-dose [18F]-FDG

Ultrafast 30-S Total-Body PET/CT Scan: a Preliminary Study

Feasibility of Low-Dose 68Ga-DOTATATE With Short Acquisition Time Using Total-Body PET/CT in Patients With Neuroendocrine Tumor

HIV SEROCONVERSION RATES IN INTRAVENOUS DRUG ABUSERS FROM NORTHERN ITALY

Patient factors affecting 18-F FDG uptake in children

Optimal activity of [18F]FDG for Hodgkin lymphoma imaging performed on PET/CT camera with BGO crystals

Optimizing Acquisition Times for Total-Body Positron Emission Tomography/computed Tomography with Half-Dose 18F-Fluorodeoxyglucose in Oncology Patients

Study on improving the quality of low-dose PET images of children based on generative adversarial networks